Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ficlatuzumab with Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer
NCT03316599Phase 1Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2018
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ficlatuzumab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Maximum Tolerated Dose at 2 years. Started Jan 2018; status: completed.
02
Drugs
ficlatuzumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03316599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03316599.